Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 75Nivolumab 46Cyclophosphamide 25aldesleukin 23fludarabine 16atezolizumab 15Ipilimumab 15Interleukin-2 14Radiosurgery 13Paclitaxel 13Specimen Handling 12Magnetic Resonance Spectroscopy 11Carboplatin 11fludarabine phosphate 9Docetaxel 9durvalumab 8Cisplatin 8cemiplimab 7Bevacizumab 7Radiotherapy 6Gemcitabine 6Biopsy 6spartalizumab 5avelumab 5Pemetrexed 5Oxaliplatin 5Immune Checkpoint Inhibitors 5Filgrastim 5Cryosurgery 5Blood Specimen Collection 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × abexinostat × Genitourinary × Clear all
NCT03590054 2024-03-22

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

University of California, San Francisco

Phase 1 Completed
35 enrolled
DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡